CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 160-169

  Albarmawi, Albader ^a   Czock, David ^a   Gauss, Annika ^b   Ehehalt, Robert ^b   Lorenzo Bermejo, Justo ^a   Burhenne, Jürgen ^a   Ganten, Tom M ^b   Sauer, Peter ^b   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Child Pugh score; cytochrome P450 CYP3A; liver cirrhosis; MELD score; midazolam; pharmacokinetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM; MIDAZOLAM MALEATE; CYP3A PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER;

ADULT; AGED; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; ANIMAL; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDAZOLAM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84891108751     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12182     Document Type: Article

References (36)

1. Verbeeck RK,. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161.
2. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S,. Dose adjustment in patients with liver disease. Drug Saf 2005; 28: 529-545.
3. Spray JW, Willett K, Chase D, Sindelar R, Connelly S,. Dosage adjustment for hepatic dysfunction based on Child-Pugh scores. Am J Health Syst Pharm 2007; 64: 690-693.
4. Amariles P, Lacampa P, Saez-Benito L,. Dosage adjustments in hepatic dysfunction. Am J Health Syst Pharm 2007; 64: 2536-2538.
5. Food and Drug Administration. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. May 2003. Available at http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf (last accessed 3 December 2012).
6. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. CPMP/EWP/2339/02. February 2005. Available at http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003122.pdf (last accessed 3 December 2012).
7. Child CG, Turcotte JG,. Surgery and portal hypertension. In: The Liver and Portal Hypertension, ed., Child CG,. Philadelphia, PA: Saunders, 1964; 50-64.
8. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
9. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR,. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580.
10. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
11. Evans WE, Relling MV,. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
12. McConn DJ 2nd, Lin YS, Mathisen TL, Blough DK, Xu Y, Hashizume T, Taylor SL, Thummel KE, Shuhart MC,. Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. Clin Pharmacol Ther 2009; 85: 387-393.
13. Andersen V, Pedersen N, Larsen NE, Sonne J, Larsen S,. Intestinal first pass metabolism of midazolam in liver cirrhosis-effect of grapefruit juice. Br J Clin Pharmacol 2002; 54: 120-124.
14. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A,. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 2008; 84: 704-709.
15. MacGilchrist AJ, Birnie GG, Cook A, Scobie G, Murray T, Watkinson G, Brodie MJ,. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986; 27: 190-195.
16. Trouvin JH, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P,. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth 1988; 60: 762-767.
17. Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoisier C,. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272-277.
18. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE,. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001; 34: 1103-1108.
19. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
21. Mosteller RD,. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
22. Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, Haefeli WE,. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem 2012; 402: 2439-2450.
23. Barre J, Mallat A, Rosenbaum J, Deforges L, Houin G, Dhumeaux D, Tillement JP,. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987; 23: 753-757.
24. Jusko WJ, Gibaldi M,. Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 1972; 61: 1270-1273.
25. Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA,. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006; 80: 235-245.
26. Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I,. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005; 77: 529-541.
27. 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38: 1227-1236.
28. Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, Stein DS,. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-826.
29. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, Wilkinson GR,. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 224-231.
30. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ,. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 2007; 81: 828-832.
31. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P,. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004; 75: 80-88.
32. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr,. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 153-158.
33. Fuhr U, Jetter A, Kirchheiner J,. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin Pharmacol Ther 2007; 81: 270-283.
34. de Vries JX, Rudi J, Walter-Sack I, Conradi R,. The determination of total and unbound midazolam in human plasma. A comparison of high performance liquid chromatography, gas chromatography and gas chromatography/mass spectrometry. Biomed Chromatogr 1990; 4: 28-33.
35. Dawson PJ, Bjorksten AR, Blake DW, Goldblatt JC,. The effects of cardiopulmonary bypass on total and unbound plasma concentrations of propofol and midazolam. J Cardiothorac Vasc Anesth 1997; 11: 556-561.
36. Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN,. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006; 80: 531-538.